thanks john, been waiting for it to come back to top up more, and was wondering about the gaps and saw them as the opportunity to buy more if they were filled.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
